Logo
x

Search

Subscribe Now

patients

Vifor and Angion's ANG-3777 Fail to Meet its Primary and Secondary Endpoint for Patients with High-Risk Kidney Transplant

Vifor and Angion's ANG-3777 Fail to Meet its Primary and Secondary Endpoint for Patients with High-Risk Kidney Transplant

  • October 27, 2021
Gan & Lee Completes P-III Studies of GL-GLA for Patients with T1D & T2D

Gan & Lee Completes P-III Studies of GL-GLA for Patients with T1D & T2D

  • October 15, 2021
Bristol Myers Squibb's Zeposia (ozanimod) Receives CHMP's Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Bristol Myers Squibb's Zeposia (ozanimod) Receives CHMP's Positive Opinion for Adult Patients with Moderately to Severely Active U...

  • October 15, 2021
Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced NSCLC

Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced NSC...

  • October 14, 2021
Novartis Reports the US FDA and EMA Filing Acceptance of Beovu for Patients with Diabetic Macular Edema

Novartis Reports the US FDA and EMA Filing Acceptance of Beovu for Patients with Diabetic Macular Edema

  • October 14, 2021
Ipsen's Cabometyx + Opdivo Receive EC's Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma

Ipsen's Cabometyx + Opdivo Receive EC's Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma

  • March 31, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.